SCHEMBL5877797

SCHEMBL5877797

Cc1ccc(S(=O)(=O)n2nc(NC3CC3)c3c2CC(c2ccc(N(C)C)cc2)(c2ccc(N(C)C)cc2)C=C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.33
GFER P55789 1/20 0.33
MCL1 Q07820 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CCR6 P51684 2/20 0.33
GPR6 P46095 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
GAA P10253 1/20 0.31
MMP2 P08253 1/20 0.31
POLB P06746 1/20 0.31
USP2 O75604 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
HSD17B10 Q99714 1/20 0.30
CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876491 0.97 ALDH1A1 (0.39) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5877313 0.96 MAPT (0.35) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5876615 0.93 ALDH1A1 (0.38) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5876542 0.90 MAPT (0.33) MAPTALDH1A1SMN1; SMN2CCR6GPR6
SCHEMBL5876609 0.89 ALDH1A1 (0.34) MAPTALDH1A1SMN1; SMN2GPR6MEN1
SCHEMBL5876040 0.89 KMT2A (0.36) MAPTSMN1; SMN2LMNACCR6GPR6
SCHEMBL5876012 0.89 NR1H2 (0.36) MAPTALDH1A1MAPK1CCR6GPR6
SCHEMBL5876928 0.88 CCR6 (0.34) MAPTALDH1A1LMNACCR6GPR6
SCHEMBL5876714 0.88 CCR6 (0.44) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5877370 0.87 MAPT (0.32) MAPTALDH1A1SMN1; SMN2MAPK1CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAPT 1879/4885ALDH1A1 166/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.